IMCAS Asia 2025: IBSA’s commitment to regenerative aesthetic medicine

IBSA Derma – the company’s dermoaesthetic division – attended the congress IMCAS Asia 2025 in Bangkok with a dedicated exhibition stand and a scientific symposium. The 18^th edition of the congress – one of the leading scientific events in the sector – took place from 6 to 8 June and welcomed over 3,000 professionals.

IMCAS Asia offered an important opportunity to consolidate IBSA Derma’s growth in the region, strengthen its dialogue with the medical community, and promote a concept of authentic beauty based on the scientific soundness of its solutions.

INNOVATION AND SCIENTIFIC VISION IN REGENERATIVE AESTHETIC MEDICINE

Held on Saturday, June 7, the scientific symposium titled The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo Line® featured internationally renowned speakers – including Dr. Lam Bee Lan and Prof. Ofir Artzi – and focused on the evolution of the regenerative approach in aesthetic medicine, with a focus on the functional impact of hyaluronic acid-based hybrid cooperative complexes (HCC) and their role in regenerating tissues across different anatomical layers affected by ageing.

HCCs represent a new frontier in the use of hyaluronic acid, made possible by NAHYCO® Technology – a patented thermal process that revolutionised the application of hyaluronic acid by extending its presence in the tissues without the need for chemical agents and enabling higher concentration.

Ten years after its launch in the field of aesthetic medicine, this technology continues to be one of the pillars of IBSA’s scientific and innovation strategy, promoting harmonious and long-lasting results while respecting the uniqueness of every patient.

EXPANSION IN THE APAC REGION AND THE DIALOGUE WITH THE MEDICAL COMMUNITY

IBSA’s participation in IMCAS Asia 2025 is part of a broader growth strategy in the Asia-Pacific region, which began with the launch of the subsidiary in Singapore and with the creation of a dedicated board for Asian key opinion leaders. Within this context, IBSA has achieved significant results in high-potential markets such as Indonesia, Vietnam, Japan and India, and has recently entered the Thai market with strong momentum.

“The significant growth we are experiencing in the APAC region”, said Loy Derris, Business Development Director of IBSA’s Dermoaesthetics Division North Asia, “is the result of well-established collaborations with local distributors, which enable us to better understand the dynamics and cultural sensitivities of each country. IMCAS Asia is a valuable opportunity to strengthen our dialogue with physicians and promote our idea of authentic beauty, rooted in a holistic vision focused on overall well-being”.

Among the most recent solutions in the field of regenerative aesthetic medicine, IBSA once again affirms its commitment to sustainable aesthetics, always listening to healthcare professionals and attentive to the real needs of patients.